Aardvark Therapeutics Shares Additional Details on Voluntary Pause of HERO Clinical Trial

Last month, we shared that Aardvark Therapeutics announced a voluntary pause in enrollment and dosing for the Phase 3 HERO clinical trial evaluating ARD-101 for hyperphagia in individuals with Prader-Willi syndrome (PWS). In a new update, Aardvark has provided additional details to help explain this decision and outline next steps. According to the announcement shared...